Literature DB >> 31940268

Top 10 Challenges in Cancer Immunotherapy.

Priti S Hegde1, Daniel S Chen2.   

Abstract

Cancer immunotherapy is a validated and critically important approach for treating patients with cancer. Given the vast research and clinical investigation efforts dedicated to advancing both endogenous and synthetic immunotherapy approaches, there is a need to focus on crucial questions and define roadblocks to the basic understanding and clinical progress. Here, we define ten key challenges facing cancer immunotherapy, which range from lack of confidence in translating pre-clinical findings to identifying optimal combinations of immune-based therapies for any given patient. Addressing these challenges will require the combined efforts of basic researchers and clinicians, and the focusing of resources to accelerate understanding of the complex interactions between cancer and the immune system and the development of improved treatment options for patients with cancer.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CAR T; T cell engagers; adaptive immune resistance; biomarkers; bispecific antibodies; cancer immune phenotypes; cancer immunotherapy; cellular therapy; immuno-oncology; intrinsic immune resistance; primary immune escape; secondary immune escape; synthetic immunity; tumor mutational burden

Year:  2020        PMID: 31940268     DOI: 10.1016/j.immuni.2019.12.011

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  333 in total

Review 1.  PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?

Authors:  Mustafa Khasraw; David A Reardon; Michael Weller; John H Sampson
Journal:  Clin Cancer Res       Date:  2020-06-11       Impact factor: 12.531

2.  Cross-Link-Functionalized Nanoparticles for Rapid Excretion in Nanotheranostic Applications.

Authors:  Zhuoran Ma; Feifei Wang; Yeteng Zhong; Felix Salazar; Jiachen Li; Mingxi Zhang; Fuqiang Ren; Anna M Wu; Hongjie Dai
Journal:  Angew Chem Weinheim Bergstr Ger       Date:  2020-07-17

3.  Pharmacogenomics for immunotherapy and immune-related cardiotoxicity.

Authors:  Jessica A Castrillon; Charis Eng; Feixiong Cheng
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

Review 4.  Cell and tissue engineering in lymph nodes for cancer immunotherapy.

Authors:  Alexander J Najibi; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2020-08-01       Impact factor: 15.470

Review 5.  Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance.

Authors:  Fang Wei; Dan Wang; Junyuan Wei; Niwen Tang; Le Tang; Fang Xiong; Can Guo; Ming Zhou; Xiaoling Li; Guiyuan Li; Wei Xiong; Shanshan Zhang; Zhaoyang Zeng
Journal:  Cell Mol Life Sci       Date:  2020-07-11       Impact factor: 9.261

Review 6.  PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential.

Authors:  Tianrui Yang; Ziren Kong; Wenbin Ma
Journal:  Hum Vaccin Immunother       Date:  2020-07-09       Impact factor: 3.452

7.  Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy.

Authors:  Chirag Krishna; Renzo G DiNatale; Fengshen Kuo; Raghvendra M Srivastava; Lynda Vuong; Diego Chowell; Sounak Gupta; Chad Vanderbilt; Tanaya A Purohit; Ming Liu; Emily Kansler; Briana G Nixon; Ying-Bei Chen; Vladimir Makarov; Kyle A Blum; Kyrollis Attalla; Stanley Weng; Michael L Salmans; Mahdi Golkaram; Li Liu; Shile Zhang; Raakhee Vijayaraghavan; Traci Pawlowski; Victor Reuter; Maria I Carlo; Martin H Voss; Jonathan Coleman; Paul Russo; Robert J Motzer; Ming O Li; Christina S Leslie; Timothy A Chan; A Ari Hakimi
Journal:  Cancer Cell       Date:  2021-04-15       Impact factor: 31.743

8.  SQ3370 Activates Cytotoxic Drug via Click Chemistry at Tumor and Elicits Sustained Responses in Injected & Non-injected Lesions.

Authors:  S Srinivasan; N A Yee; K Wu; M Zakharian; A Mahmoodi; M Royzen; J M Mejia Oneto
Journal:  Adv Ther (Weinh)       Date:  2021-01-20

9.  Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.

Authors:  Guoqing Qian; Jianping Guo; Karin A Vallega; Changjiang Hu; Zhen Chen; Yunfu Deng; Qiming Wang; Songqing Fan; Suresh S Ramalingam; Taofeek K Owonikoko; Wenyi Wei; Shi-Yong Sun
Journal:  Mol Cancer Res       Date:  2021-06-28       Impact factor: 5.852

10.  Rapid Serial Immunoprofiling of the Tumor Immune Microenvironment by Fine Needle Sampling.

Authors:  Juhyun Oh; Jonathan C T Carlson; Christian Landeros; Hakho Lee; Scott Ferguson; William C Faquin; John R Clark; Mikael J Pittet; Sara I Pai; Ralph Weissleder
Journal:  Clin Cancer Res       Date:  2021-07-07       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.